Veru is a healthcare company focusing on oncology, biopharmaceuticals, and urology specialty pharmaceuticals. Founded in 1971 in Miami, FL, the company aims to improve lives through innovative science and medicine as a leading biopharmaceutical player in the fields of urology and oncology.
With 252 employees and an annual revenue of $39.4M, Veru is dedicated to developing and commercializing novel medicines for prostate cancer and other urological conditions. The company's CEO, Mitchell Shuster Steiner, guides Veru's mission to enhance stakeholder value while positively impacting the lives of patients worldwide.
